Cargando…

Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy

BACKGROUND: The multitargeting tyrosine kinase inhibitor (TKI) sunitinib is currently the first-line drug therapy for metastasizing renal cell carcinoma (RCC). TKIs have profound effects on tumor angiogenesis, leading to modifications of the tumor microenvironment. The goal of this study was to dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chapman, David W, Jans, Hans-Sonke, Ma, Ivy, Mercer, John R, Wiebe, Leonard I, Wuest, Melinda, Moore, Ronald B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451188/ https://www.ncbi.nlm.nih.gov/pubmed/26116107 http://dx.doi.org/10.1186/s13550-014-0027-5

Ejemplares similares

First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer
por: Thureau, Sébastien, et al.
Publicado: (2021)

Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
por: Verhoeven, Jeroen, et al.
Publicado: (2019)

Hypoxia imaging with (18)F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts
por: Melsens, Elodie, et al.
Publicado: (2018)

Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [(18)F]-fluoro-azomycinarabino-furanoside ([(18)F]FAZA)
por: Maier, Florian C, et al.
Publicado: (2011)

Kinetic Evaluation of the Hypoxia Radiotracers [(18)F]FMISO and [(18)F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging
por: Choen, Sangkyung, et al.
Publicado: (2022)

Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
por: Gammon, Seth T., et al.
Publicado: (2019)

Comparison of scandium-44 g with other PET radionuclides in pre-clinical PET phantom imaging
por: Ferguson, Simon, et al.
Publicado: (2019)

Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
por: Zheng, Jinzi, et al.
Publicado: (2015)

Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models
por: Bouvet, Vincent, et al.
Publicado: (2016)

In vitro hypoxia responsiveness of [(18)F] FDG and [(18)F] FAZA retention: influence of shaking versus stagnant conditions, glass versus polystyrene substrata and cell number down-scaling
por: Busk, Morten, et al.
Publicado: (2020)

A Comparative pO(2) Probe and [(18)F]-Fluoro-Azomycinarabino-Furanoside ([(18)F]FAZA) PET Study Reveals Anesthesia-Induced Impairment of Oxygenation and Perfusion in Tumor and Muscle
por: Mahling, Moritz, et al.
Publicado: (2015)

(18)FDG, [(18)F]FLT, [(18)F]FAZA, and (11)C-Methionine Are Suitable Tracers for the Diagnosis and In Vivo Follow-Up of the Efficacy of Chemotherapy by miniPET in Both Multidrug Resistant and Sensitive Human Gynecologic Tumor Xenografts
por: Trencsényi, György, et al.
Publicado: (2014)

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC)
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

Abdelazim and AbuFaza ELLP syndrome as a variant of HELLP syndrome: Case reports
por: Abdelazim, Ibrahim A., et al.
Publicado: (2019)

Toward in vivo proof of binding of (18)F-labeled inhibitor [(18)F]TRACK to peripheral tropomyosin receptor kinases
por: Wuest, Melinda, et al.
Publicado: (2022)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

(18)F-Labeled Peptides: The Future Is Bright
por: Richter, Susan, et al.
Publicado: (2014)

Advances in [(18)F]Trifluoromethylation Chemistry for PET Imaging
por: Francis, Felix, et al.
Publicado: (2021)

PET Imaging of Fructose Metabolism in a Rodent Model of Neuroinflammation with 6-[(18)F]fluoro-6-deoxy-D-fructose
por: Boyle, Amanda J., et al.
Publicado: (2022)

Abdelazim and AbuFaza technique for temporary bilateral uterine occlusion to decrease the blood loss during myomectomy: Case reports
por: Abdelazim, Ibrahim A., et al.
Publicado: (2019)

Synthesis of a 2-nitroimidazole derivative N-(4-[(18)F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([(18) F]FBNA) as PET radiotracer for imaging tumor hypoxia
por: Nario, Arian Pérez, et al.
Publicado: (2022)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Automated synthesis of an (18)F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation
por: von Guggenberg, Elisabeth, et al.
Publicado: (2009)

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma
por: Thézé, Benoît, et al.
Publicado: (2015)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Chen, Ying-Shou, et al.
Publicado: (2009)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
por: Deeken, John F, et al.
Publicado: (2012)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6gtucekogo7l2bkd3bljhi5uq4